The TRIPLEX study: use of patient-derived tumor organoids as an innovative tool for precision medicine in triple-negative breast cancer

BACKGROUND: Triple negative breast cancers (TNBC) account for approximately 15% of all breast cancers and are associated with a shorter median survival mainly due to locally advanced tumor and high risk of metastasis. The current neoadjuvant treatment for TNBC consists of a regimen of immune checkpo...

Descripción completa

Detalles Bibliográficos
Autores principales: Divoux, Jordane, Florent, Romane, Jacobs, Margaux, Lequesne, Justine, Grellard, Jean-Michel, San, Chankannira, Grossi, Sara, Kerdja, Katia, Clarisse, Bénédicte, Boudier, Gwenaelle, Cherifi, François, Briand, Mélanie, Dolivet, Enora, Johnson, Alisson, Dubois, Brice, Harter, Valentin, Lacroix, Joëlle, Raboutet, Charlotte, Marie, Brigitte, Rousseau, Nathalie, Blanc-Fournier, Cécile, Vaur, Dominique, Figeac, Martin, Poulain, Laurent, Weiswald, Louis-Bastien, Emile, George
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10508010/
https://www.ncbi.nlm.nih.gov/pubmed/37726786
http://dx.doi.org/10.1186/s12885-023-11362-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10508010/
https://www.ncbi.nlm.nih.gov/pubmed/37726786
http://dx.doi.org/10.1186/s12885-023-11362-8

Ejemplares similares